Get the Stockscreener App
16.98
1.45%
-0.25
After Hours:
16.88
-0.10
-0.59%
Quince Therapeutics Inc stock is traded at $16.98, with a volume of 18,912.
It is down -1.45% in the last 24 hours and down -15.94% over the past month.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
See More
Previous Close:
$17.23
Open:
$17.21
24h Volume:
18,912
Relative Volume:
0.08
Market Cap:
$16.61M
Revenue:
-
Net Income/Loss:
$-33.04M
P/E Ratio:
-1.8655
EPS:
-9.1023
Net Cash Flow:
$-39.66M
1W Performance:
-7.78%
1M Performance:
-15.94%
6M Performance:
-96.95%
1Y Performance:
-94.73%
1-Day Range:
$16.82
$17.53
1-Week Range:
$15.10
$19.26
52-Week Range:
$15.10
$909.98
Quince Therapeutics Inc Stock (QNCX) Company Profile
Name
Quince Therapeutics Inc
Sector
Industry
Phone
415-910-5717
Address
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
16.98 | 17.79M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
Quince Therapeutics Inc Stock (QNCX) Latest News
HCW Biologics Inc.: Top Mutual Funds Holders | QNCX | US40423R3030 - marketscreener.com
Quince Therapeutics forms advisory board for LAM-001 drug - Investing.com
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board - GlobeNewswire
Quince Therapeutics, Inc. Files 8-K/A Amendment to Correct Reverse Stock Split Description – Key SEC Filing Details - Minichart
Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction - Stock Titan
1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares - Stock Titan
Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to book forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX) - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com - Investing.com South Africa
QNCX Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight - Investing.com
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating - Investing.com
Cantor Fitzgerald Maintains Quince Therapeutics(QNCX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
$Quince Therapeutics (QNCX.US)$ - Moomoo
QNCX Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Leerink initiates Quince Therapeutics stock with Outperform rating By Investing.com - Investing.com Australia
Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target - marketscreener.com
Leerink initiates Quince Therapeutics stock with Outperform rating - Investing.com
QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating - Investing.com UK
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating By Investing.com - Investing.com South Africa
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
Stay encouraged and keep believing in yourself - Moomoo
Cantor Fitzgerald Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Stockbackground, strategy and long-term outlook - AD HOC NEWS
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan
Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan
Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026) - Minichart
Quince Therapeutics Stock (US74833Q1004): Stock in focus after shareholder analyst call - AD HOC NEWS
Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan
Quince Therapeutics, Inc. announced that it has received $115.000298 million in funding from a group of investors - marketscreener.com
[SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
QNCX Q1 2026 Earnings: Unexpected Profit Driven by One-Time Items; Shares DipSurprise Factor Analysis - newsline.com
Quince Therapeutics Inc Stock (QNCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quince Therapeutics Inc Stock (QNCX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Benatti Luca | Director |
Dec 26 '25 |
Sale |
3.47 |
50,000 |
173,500 |
39,179 |
| Hannah Brendan | CBO, COO & CCO |
Dec 05 '25 |
Option Exercise |
0.91 |
27,551 |
25,012 |
361,827 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):